Quantification of tumor cell burden by analysis of single cell lymph node disaggregates in metastatic prostate cancer

The Prostate ◽  
2010 ◽  
Vol 70 (10) ◽  
pp. 1110-1118 ◽  
Author(s):  
David Schilling ◽  
Joerg Hennenlotter ◽  
Karl Sotlar ◽  
Ursula Kuehs ◽  
Erika Senger ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Tumor Cell ◽  
Single Cell ◽  
Metastatic Prostate Cancer

scholarly journals Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e042953
Author(s):  
Martin John Connor ◽  
Taimur Tariq Shah ◽  
Katarzyna Smigielska ◽  
Emily Day ◽  
Johanna Sukumar ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Androgen Receptor ◽  
Randomised Controlled Trial ◽  
Phase Ii ◽  
Metastatic Prostate Cancer ◽  
Controlled Trial ◽  
Pelvic Lymph Node ◽  
Study Results ◽  
Randomised Controlled

IntroductionSurvival in men diagnosed with de novo synchronous metastatic prostate cancer has increased following the use of upfront systemic treatment, using chemotherapy and other novel androgen receptor targeted agents, in addition to standard androgen deprivation therapy (ADT). Local cytoreductive and metastasis-directed interventions are hypothesised to confer additional survival benefit. In this setting, IP2-ATLANTA will explore progression-free survival (PFS) outcomes with the addition of sequential multimodal local and metastasis-directed treatments compared with standard care alone.MethodsA phase II, prospective, multicentre, three-arm randomised controlled trial incorporating an embedded feasibility pilot. All men with new histologically diagnosed, hormone-sensitive, metastatic prostate cancer, within 4 months of commencing ADT and of performance status 0 to 2 are eligible. Patients will be randomised to Control (standard of care (SOC)) OR Intervention 1 (minimally invasive ablative therapy to prostate±pelvic lymph node dissection (PLND)) OR Intervention 2 (cytoreductive radical prostatectomy±PLND OR prostate radiotherapy±pelvic lymph node radiotherapy (PLNRT)). Metastatic burden will be prespecified using the Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease (CHAARTED) definition. Men with low burden disease in intervention arms are eligible for metastasis-directed therapy, in the form of stereotactic ablative body radiotherapy (SABR) or surgery. Standard systemic therapy will be administered in all arms with ADT±upfront systemic chemotherapy or androgen receptor agents. Patients will be followed-up for a minimum of 2 years. Primary outcome: PFS. Secondary outcomes include predictive factors for PFS and overall survival; urinary, sexual and rectal side effects. Embedded feasibility sample size is 80, with 918 patients required in the main phase II component. Study recruitment commenced in April 2019, with planned follow-up completed by April 2024.Ethics and disseminationApproved by the Health Research Authority (HRA) Research Ethics Committee Wales-5 (19/WA0005). Study results will be submitted for publication in peer-reviewed journals.Trial registration numberNCT03763253; ISCRTN58401737

scholarly journals Author Correction: Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Vincenza Conteduca ◽  
Sheng-Yu Ku ◽  
Luisa Fernandez ◽  
Angel Dago-Rodriquez ◽  
Jerry Lee ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Cell ◽  
Single Cell ◽  
Copy Number ◽  
Circulating Tumor Cell ◽  
Cell Heterogeneity ◽  
Copy Number Analysis ◽  
Neuroendocrine Prostate Cancer ◽  
Tumor Cell Heterogeneity

Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients

2019 ◽  
Vol 5 (3) ◽  
pp. 381-388 ◽  
Author(s):  
Marco Bandini ◽  
Felix Preisser ◽  
Sebastiano Nazzani ◽  
Michele Marchioni ◽  
Zhe Tian ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Metastatic Prostate Cancer ◽  
Survival Outcomes

scholarly journals Clinical outcomes of definitive whole pelvic radiotherapy for clinical lymph node metastatic prostate cancer

2020 ◽  
Vol 9 (18) ◽  
pp. 6629-6637
Author(s):  
Keisuke Tsuchida ◽  
Koji Inaba ◽  
Tairo Kashihara ◽  
Naoya Murakami ◽  
Kae Okuma ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Clinical Outcomes ◽  
Metastatic Prostate Cancer ◽  
Pelvic Radiotherapy

PCA3 and PSA gene activity correlates with the true tumor cell burden in prostate cancer lymph node metastases

2015 ◽  
Vol 15 (3) ◽  
pp. 311-316 ◽  
Author(s):  
Igor Tsaur ◽  
Joerg Hennenlotter ◽  
Elsie Oppermann ◽  
Marita Munz ◽  
Ursula Kuehs ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Tumor Cell ◽  
Lymph Node Metastases ◽  
Gene Activity ◽  
Node Metastases

scholarly journals Circulating tumor cell in hormone-naive metastatic prostate cancer

2017 ◽  
Vol 28 ◽  
pp. x79
Author(s):  
M. Kanayama ◽  
N. Nagaya ◽  
M. Nagata ◽  
S. Horie
Keyword(s):  
Prostate Cancer ◽  
Tumor Cell ◽  
Metastatic Prostate Cancer ◽  
Circulating Tumor Cell

Robotic Image-Guided Stereotactic Radiotherapy, for Isolated Recurrent Primary, Lymph Node or Metastatic Prostate Cancer

2012 ◽  
Vol 82 (2) ◽  
pp. 889-897 ◽  
Author(s):  
Barbara Alicja Jereczek-Fossa ◽  
Giancarlo Beltramo ◽  
Laura Fariselli ◽  
Cristiana Fodor ◽  
Luigi Santoro ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Stereotactic Radiotherapy ◽  
Metastatic Prostate Cancer ◽  
Image Guided ◽  
Primary Lymph Node

scholarly journals Generalized Lymphadenopathy: Unusual Presentation of Prostate Adenocarcinoma

2011 ◽  
Vol 2011 ◽  
pp. 1-3 ◽  
Author(s):  
Bulent Cetin ◽  
Zeynep Cetin ◽  
Suleyman Buyukberber ◽  
Ipek Isık Gonul ◽  
Ilgin Sahiner ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Prostate Biopsy ◽  
Immunohistochemical Staining ◽  
Metastatic Prostate Cancer ◽  
Inguinal Lymph Node ◽  
Prostate Adenocarcinoma ◽  
Rare Manifestation ◽  
Inguinal Lymphadenopathy ◽  
Generalized Lymphadenopathy

Generalized lymphadenopathy is a rare manifestation of metastatic prostate cancer. Here, we report the case of a 59-year-old male patient with supraclavicular, mediastinal, hilar, and retroperitoneal and inguinal lymphadenopathy, which suggested the diagnosis of lymphoma. There were no urinary symptoms. A biopsy of the inguinal lymph node was compatible with adenocarcinoma, whose prostatic origin was shown by immunohistochemical staining with PSA. The origin of the primary tumor was confirmed by directed prostate biopsy. We emphasize that a suspicion of prostate cancer in men with adenocarcinoma of undetermined origin is important for an adequate diagnostic and therapeutic approach.

scholarly journals 177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer

Oncotarget ◽  
2019 ◽  
Vol 10 (25) ◽  
pp. 2451-2461 ◽  
Author(s):  
Finn Edler von Eyben ◽  
Aviral Singh ◽  
Jingjing Zhang ◽  
Karin Nipsch ◽  
Danielle Meyrick ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Metastatic Prostate Cancer ◽  
Radioligand Therapy
Sign in / Sign up

Export Citation Format

Share Document